ATE549021T1 - Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil - Google Patents

Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil

Info

Publication number
ATE549021T1
ATE549021T1 AT07867284T AT07867284T ATE549021T1 AT E549021 T1 ATE549021 T1 AT E549021T1 AT 07867284 T AT07867284 T AT 07867284T AT 07867284 T AT07867284 T AT 07867284T AT E549021 T1 ATE549021 T1 AT E549021T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
dimebon
combination therapies
donepezil
Prior art date
Application number
AT07867284T
Other languages
English (en)
Inventor
David T Hung
Andrew Asher Protter
Original Assignee
Medivation Neurology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Neurology Inc filed Critical Medivation Neurology Inc
Application granted granted Critical
Publication of ATE549021T1 publication Critical patent/ATE549021T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07867284T 2006-10-27 2007-10-26 Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil ATE549021T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85486606P 2006-10-27 2006-10-27
PCT/US2007/022645 WO2008051599A2 (en) 2006-10-27 2007-10-26 Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil

Publications (1)

Publication Number Publication Date
ATE549021T1 true ATE549021T1 (de) 2012-03-15

Family

ID=39315586

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07867284T ATE549021T1 (de) 2006-10-27 2007-10-26 Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil

Country Status (15)

Country Link
US (1) US20100152108A1 (de)
EP (2) EP2086538B1 (de)
JP (1) JP2010507672A (de)
KR (1) KR20090087009A (de)
CN (1) CN101631547A (de)
AT (1) ATE549021T1 (de)
AU (1) AU2007309390A1 (de)
BR (1) BRPI0718437A2 (de)
CA (1) CA2667553A1 (de)
IL (2) IL198405A0 (de)
MX (1) MX2009004516A (de)
NO (1) NO20092051L (de)
RU (1) RU2009120048A (de)
SG (1) SG178000A1 (de)
WO (1) WO2008051599A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
RU2334514C1 (ru) * 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
EA016234B1 (ru) * 2007-04-05 2012-03-30 Андрей Александрович ИВАЩЕНКО ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
MX2010003149A (es) 2007-09-20 2010-11-10 D2E Llc Derivados que contienen fluor de pirido[4,3-b]indoles hidrogenados con propiedades neuroprotectoras y de mejoramiento de cognicion, proceso de preparacion y uso.
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8546381B2 (en) 2008-03-24 2013-10-01 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
WO2009120717A2 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
JP2012502915A (ja) 2008-09-15 2012-02-02 バイオビスタ インコーポレイテッド てんかんを治療する組成物及び方法
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
TW201018694A (en) 2008-09-29 2010-05-16 Abbott Lab Indole and indoline derivatives and methods of use thereof
US8907097B2 (en) 2008-10-31 2014-12-09 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
AU2009308708B2 (en) 2008-10-31 2015-11-19 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
US20100125085A1 (en) * 2008-11-17 2010-05-20 Auspex Pharmaceuticals, Inc. Pyridoindole modulators of nmda receptor and acetylcholinesterase
EP2381955A4 (de) * 2008-12-30 2013-01-16 Univ Ramot Kombinationstherapien mit nap
KR20110132564A (ko) * 2009-02-11 2011-12-08 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
EP2417973B1 (de) 2009-04-10 2013-08-28 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. Retardzusammensetzung mit tetrahydropyrido[4, 3-b]indol-derivat
WO2011019417A1 (en) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
CN102480955B (zh) * 2009-04-29 2015-08-05 梅迪维新技术公司 吡啶并[4,3-b]吲哚类和使用方法
CA2772525A1 (en) * 2009-09-11 2011-03-17 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011038163A1 (en) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
WO2011038164A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
BR112012006640A2 (pt) 2009-09-23 2019-09-24 Medivation Technologies Inc composto, composição farmacêutica, método de tratamento de um distúrbio cognitivo, distúrbiopsocótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit
WO2011039675A2 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine transdermal therapeutic dosage forms
WO2011100373A1 (en) * 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
TR201001117A1 (tr) * 2010-02-15 2011-09-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Dimebolin ve memantin kombinasyonları
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2012016708A1 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
NZ707955A (en) 2010-09-23 2016-03-31 Abbvie Bahamas Ltd Monohydrate of an azaadamantane derivative
JP2014505737A (ja) 2011-02-18 2014-03-06 メディベイション テクノロジーズ， インコーポレイテッド 糖尿病を処置する化合物および方法
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2012112962A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012122405A2 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Screening assays using stem cells and stem cell-derived neurons from mouse models of alzheimer's disease
DE102012003065A1 (de) * 2012-02-13 2013-08-14 Friedrich-Schiller-Universität Jena Neue bivalente Gammacarbolinderivate sowie deren Herstellung und Verwendung als Antidementiva
US20150018362A1 (en) 2012-02-27 2015-01-15 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US20150166617A1 (en) * 2012-06-27 2015-06-18 University Of Miami Compositions and methods of treating alzheimer's disease
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
RU2496465C1 (ru) * 2012-11-15 2013-10-27 Борис Николаевич Анисимов Способ профилактики развития и прогрессирования болезни альцгеймера на курортном этапе
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
EP3827820A1 (de) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam zur verbesserung der kognitiven funktion
WO2016179217A1 (en) * 2015-05-06 2016-11-10 Ohio University Metal ion chelation for enhancing the effect of tissue plasminogen activator (tpa) in thromobolysis
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US10639315B1 (en) 2019-05-21 2020-05-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating Alzheimer's disease
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
WO2020236159A1 (en) * 2019-05-21 2020-11-26 La Pharma Tech Inc. Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
AU2021289147A1 (en) * 2020-06-12 2023-02-02 Beckley Psytech Limited Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1245155A (en) 1967-12-08 1971-09-08 Sumitomo Chemical Co NOVEL 5-SUBSTITUTED-gamma-CARBOLINE DERIVATIVES AND THE SALTS THEREOF
DE1952800C3 (de) 1969-10-20 1974-04-18 Nautschno-Issledowatelskij Institut Farmakologii I Chimioterapii, Moskau 3,6-Dimethyl-l,2,3,4,4a,9a-hexahydro-gamma-carbolin-dihydrochlorid
US3718657A (en) 1970-12-03 1973-02-27 Abbott Lab Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
TW506836B (en) 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
JPH10259126A (ja) * 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
EP1048653B1 (de) 1997-12-05 2004-03-03 Eisai Co., Ltd. Donepezil polykristalle und verfharen zu ihrer herstellung
PT1086706E (pt) 1999-03-31 2004-02-27 Eisai Co Ltd Composicao estabilizada que compreende um medicamento nootropico
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
AU2003274353B2 (en) * 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CA2529535A1 (en) * 2003-06-16 2004-12-29 Allergan, Inc. Memantine oral dosage forms
RU2283108C2 (ru) 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20060270709A1 (en) * 2005-04-04 2006-11-30 Eisai Co. Ltd. Dihydropyridine compounds and compositions for headaches

Also Published As

Publication number Publication date
RU2009120048A (ru) 2010-12-10
EP2420235A1 (de) 2012-02-22
US20100152108A1 (en) 2010-06-17
IL219709A0 (en) 2012-06-28
JP2010507672A (ja) 2010-03-11
MX2009004516A (es) 2009-08-12
KR20090087009A (ko) 2009-08-14
WO2008051599A3 (en) 2008-07-24
BRPI0718437A2 (pt) 2013-11-19
WO2008051599A2 (en) 2008-05-02
CA2667553A1 (en) 2008-05-02
IL198405A0 (en) 2010-02-17
NO20092051L (no) 2009-07-22
CN101631547A (zh) 2010-01-20
AU2007309390A1 (en) 2008-05-02
EP2086538B1 (de) 2012-03-14
EP2086538A2 (de) 2009-08-12
SG178000A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
ATE549021T1 (de) Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
ATE425965T1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
NO20071267L (no) Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer
WO2007041697A3 (en) Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
GB2442915B (en) Perylenequinone derivatives and uses thereof
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
SI1660057T1 (sl) Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
DE602004008069D1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
WO2005107726A3 (en) Method for the treatment of back pain
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
PL1966209T3 (pl) [1H-Indol-5-ilo)-heteroaryloksy]-(1-aza-bicyklo[3.3.1]nonany jako ligandy cholinergiczne dla nAChR do leczenia zaburzeń psychotycznych i neurodegeneracyjnych
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE445401T1 (de) Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit
WO2007039123A3 (en) Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
BRPI0807867A2 (pt) Derivado de indol ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um derivado de (indol-3-il) heterociclo, e, método de tratamento de dor
DE60327335D1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
ATE366720T1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose